Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Current Assets (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Current Assets for 11 consecutive years, with $202.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 26.78% to $202.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $202.7 million through Dec 2025, down 26.78% year-over-year, with the annual reading at $202.7 million for FY2025, 26.78% down from the prior year.
  • Current Assets hit $202.7 million in Q4 2025 for Voyager Therapeutics, down from $219.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $409.1 million in Q1 2024 to a low of $124.5 million in Q4 2022.
  • Historically, Current Assets has averaged $234.2 million across 5 years, with a median of $223.7 million in 2025.
  • Biggest five-year swings in Current Assets: plummeted 41.66% in 2021 and later surged 156.78% in 2023.
  • Year by year, Current Assets stood at $136.7 million in 2021, then dropped by 8.92% to $124.5 million in 2022, then skyrocketed by 156.78% to $319.7 million in 2023, then fell by 13.41% to $276.8 million in 2024, then decreased by 26.78% to $202.7 million in 2025.
  • Business Quant data shows Current Assets for VYGR at $202.7 million in Q4 2025, $219.6 million in Q3 2025, and $227.9 million in Q2 2025.